2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Hatch-Waxman Patent Litigation (Generic)
| Hatch-Waxman Patent Litigation (Generic) — Highly Recommended |
|---|
| Goodwin Procter |
| Knobbe Martens |
| Rakoczy Molino Mazzochi Siwik |
| Sterne Kessler Goldstein & Fox |
| Wilson Sonsini Goodrich & Rosati |
| Winston & Strawn |
| Hatch-Waxman Patent Litigation (Generic) — Recommended |
|---|
| Axinn Veltrop & Harkrider |
| Greenberg Traurig |
| Morrison & Foerster |
| Perkins Coie |
| Robins Kaplan |
| Rothwell Figg Ernst & Manbeck |
| Taft Stettinius & Hollister |
| Willkie Farr & Gallagher |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Holdreith, Jake M | Intellectual Property | Patent Strategy & Management, General Patent Litigation, Hatch-Waxman Patent Litigation | Minneapolis |
| Hovden, Jeffrey | Intellectual Property | Hatch-Waxman Patent Litigation | New York City |
| Langer, Oren | Intellectual Property | Hatch-Waxman Patent Litigation | New York City |
| Schutz, Ronald J | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | New York City |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
Robins Kaplan
Minneapolis-based Robins Kaplan is nationally recommended for its IP group focused on generic Hatch-Waxman litigation. A client says the IP team is "thoughtful and methodical in its work on our behalf in a number of high-stakes litigation matters," and "repeatedly demonstrates that our interests are 'top of mind' for them."
Health and life sciences industry group chair Jake Holdreith is focused on pharmaceutical patent litigation for the firm's generic clientele. He is currently active for Collegium Pharmaceutical as lead counsel in a series of cases involving patents owned by Purdue. The case has been stayed due to Purdue’s recent bankruptcy declaration. In another matter, Holdreith is representing Amneal as trial counsel against Amgen related to the opponent’s branded Sensipar product. Ronald Schutz is a notable litigator at the firm, and currently serves as chair of the executive board.
New to the LMG Life Sciences Stars list are Jeffrey Hovden and Oren Langer, both experienced practitioners in the patent litigation arena. They are currently representing Torrent Pharmaceuticals in a Hatch-Waxman dispute against Bial-Portela and Sunovion.